拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

已收盘 01-06 16:00:00 EST

60.07

+1.20

+2.04%

盘后60.21

+0.14+0.23%

19:56 EST

最高60.46	最低58.87	成交量201.93万
今开58.87	昨收58.87	日振幅2.70%
总市值115.40亿	流通市值106.98亿	总股本1.92亿
成交额1.21亿	换手率1.13%	流通股本1.78亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":60.07,"timestamp":1767733200000,"preClose":58.87,"halted":0,"volume":2019347,"hourTrading":{"tag":"盘后","latestPrice":60.21,"preClose":60.07,"latestTime":"19:56 EST","volume":60706,"amount":3646619.012,"timestamp":1767747401850},"delay":0,"floatShares":178100339,"shares":192114344,"eps":2.680754,"marketStatus":"已收盘","change":1.2,"latestTime":"01-06 16:00:00 EST","open":58.87,"high":60.4623,"low":58.87,"amount":121031282.92864399,"amplitude":0.027048,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.680754,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767776400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":58.87,"preHourTrading":{"tag":"盘前","latestPrice":59.25,"preClose":58.87,"latestTime":"09:10 EST","volume":890,"amount":52774.82662,"timestamp":1767708607700},"postHourTrading":{"tag":"盘后","latestPrice":60.21,"preClose":60.07,"latestTime":"19:56 EST","volume":60706,"amount":3646619.012,"timestamp":1767747401850},"volumeRatio":1.259364,"impliedVol":0.3608,"impliedVolPercentile":0.4},"requestUrl":"/m/hq/s/BMRN","defaultTab":"news","newsList":[{"id":"1122318998","title":"拜玛林制药 - 停止开发口服治疗阿尔法-1抗胰蛋白酶缺乏症（AATD）的Bmn 349 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1122318998","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122318998?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:08","pubTimestamp":1766412526,"startTime":"0","endTime":"0","summary":"拜玛林制药 - 停止开发口服治疗阿尔法-1抗胰蛋白酶缺乏症（AATD）的Bmn 349 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BMRN","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4139","BK4566","IE0002270589.USD"],"gpt_icon":0},{"id":"1187502050","title":"拜玛林制药：根据合并协议终止，阿米库斯将支付拜玛林1.75亿美元的终止费用 - SEC提交文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1187502050","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187502050?lang=zh_cn&edition=full","pubTime":"2025-12-19 21:52","pubTimestamp":1766152334,"startTime":"0","endTime":"0","summary":"拜玛林制药：根据合并协议终止，阿米库斯将支付拜玛林1.75亿美元的终止费用 - SEC提交文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4566","BMRN","BK4139","IE0002270589.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"1191463279","title":"爱美医疗股价在盘前交易中上涨30%，拜玛林制药将以48亿美元收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1191463279","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191463279?lang=zh_cn&edition=full","pubTime":"2025-12-19 21:13","pubTimestamp":1766149995,"startTime":"0","endTime":"0","summary":"爱美医疗股价在盘前交易中上涨30%，拜玛林制药将以48亿美元收购该公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BK4139","FOLD","LU2065169927.USD","LU2065170008.USD","IE0002270589.USD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU2065171311.SGD","BK4566","BMRN","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"1174007364","title":"拜玛林制药以48亿美元收购爱美医疗，巩固稀有疾病领域的领导地位，推动收入增长，增强财务前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1174007364","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174007364?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148765,"startTime":"0","endTime":"0","summary":"拜玛林制药以48亿美元收购爱美医疗，巩固稀有疾病领域的领导地位，推动收入增长，增强财务前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BMRN","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4139","LU2065171402.SGD","BK4566","LU2065169927.USD","IE0002270589.USD","FOLD","LU2065171311.SGD","LU2065170008.USD"],"gpt_icon":0},{"id":"1159090067","title":"爱美医疗将于2037年1月30日授予Aurobindo和Lupin在美国市场销售Galafold的仿制药许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1159090067","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159090067?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148759,"startTime":"0","endTime":"0","summary":"爱美医疗将于2037年1月30日授予Aurobindo和Lupin在美国市场销售Galafold的仿制药许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU2065169927.USD","LU2065171311.SGD","LU2065171402.SGD","BMRN","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU2065170008.USD","FOLD","BK4139","IE00B19Z3581.USD","BK4566"],"gpt_icon":0},{"id":"1168785237","title":"爱美医疗：交易将于2027年开始显著提升拜玛林制药的非GAAP稀释每股收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1168785237","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168785237?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:48","pubTimestamp":1766148494,"startTime":"0","endTime":"0","summary":"爱美医疗：交易将于2027年开始显著提升拜玛林制药的非GAAP稀释每股收益","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4566","LU2065170008.USD","BMRN","LU2065171402.SGD","BK4139","LU2065169927.USD","IE0002270589.USD","IE00B7SZLL34.SGD","LU2065171311.SGD","FOLD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"1168884106","title":"摩根士丹利：这些“潜在分红股”若启动派息，或将带来可观回报","url":"https://stock-news.laohu8.com/highlight/detail?id=1168884106","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168884106?lang=zh_cn&edition=full","pubTime":"2025-11-11 11:20","pubTimestamp":1762831244,"startTime":"0","endTime":"0","summary":"根据摩根士丹利的分析，一些美股公司具备财务实力，有能力开始向股东支付股息。为了寻找这些“潜在分红股”，卡斯塔尼奥筛选出了那些目前尚未支付季度股息、净现金占市值比例超过5%、自由现金流收益率高于3%的公司。摩根士丹利指出，Schwab的净现金占市值比例为12.3%，自由现金流收益率为8.7%。其股价年初至今上涨约29%。Twilio预计2025年的自由现金流将在9.2亿至9.3亿美元之间。其股价今年迄今上涨近21%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/5f85c955e3208ef4eece8dcd45934bb7","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/5f85c955e3208ef4eece8dcd45934bb7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1a9184b88c2cdb4d7f1e15ff04a6a973","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCHW","ABNB","SAM","LYFT","INCY","NYT","TWLO","CART","DDS","BMRN"],"gpt_icon":1},{"id":"2578966978","title":"BioMarin为其药物VOXZOGO设定2025年9-9.35亿美元营收目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2578966978","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578966978?lang=zh_cn&edition=full","pubTime":"2025-10-28 23:00","pubTimestamp":1761663632,"startTime":"0","endTime":"0","summary":"美股周二早盘，生物技术企业BioMarin Pharmaceutical （BMRN）股价上涨4.4%，此前该公司为其药物VOXZOGO设定2025年9-9.35亿美元营收目标。尽管整体业务表现强劲，公司仍计划剥离ROCTAVIAN产品以聚焦战略重点。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-28/doc-infvnhpi1031324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IE00B19Z3581.USD","SINA","IE00B19Z3B42.SGD","BK4566","BMRN","IE00B7SZLL34.SGD","BK4139","IE0002270589.USD"],"gpt_icon":0},{"id":"1126115775","title":"拜玛林制药：将在美国、意大利和德国继续商业供应Roctavian，直至下一步措施确定","url":"https://stock-news.laohu8.com/highlight/detail?id=1126115775","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126115775?lang=zh_cn&edition=full","pubTime":"2025-10-28 04:23","pubTimestamp":1761596631,"startTime":"0","endTime":"0","summary":"拜玛林制药：将在美国、意大利和德国继续商业供应Roctavian，直至下一步措施确定","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BMRN","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4139","BK4566","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"1180747900","title":"拜玛林制药第三季度预计因Inozyme Pharma交易产生约1.10美元的GAAP和非GAAP每股收益费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1180747900","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180747900?lang=zh_cn&edition=full","pubTime":"2025-10-08 05:22","pubTimestamp":1759872151,"startTime":"0","endTime":"0","summary":"拜玛林制药公司表示，预计第三季度因Inozyme Pharma交易将对GAAP和非GAAP每股收益产生约1.10美元的费用影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B19Z3581.USD","BMRN","BK4566","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"1169021884","title":"拜玛林制药：预计第三季度将因收购Inoozyme Pharma交易产生约2.21亿美元税前已收购研发资产费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1169021884","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169021884?lang=zh_cn&edition=full","pubTime":"2025-10-08 05:20","pubTimestamp":1759872020,"startTime":"0","endTime":"0","summary":"拜玛林制药预计，由于收购Inoozyme Pharma的交易，第三季度将产生约2.21亿美元的已收购研发资产费用（税前基础）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BMRN","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3581.USD","BK4139"],"gpt_icon":0},{"id":"1108040225","title":"拜玛林制药：H.C. Wainwright首次覆盖并给予中性评级，目标价60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108040225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108040225?lang=zh_cn&edition=full","pubTime":"2025-09-08 18:48","pubTimestamp":1757328496,"startTime":"0","endTime":"0","summary":"拜玛林制药：H.C. Wainwright首次覆盖并给予中性评级，目标价60美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4139","BK4566","IE00B19Z3581.USD","BMRN"],"gpt_icon":0},{"id":"1174292197","title":"Biomarin在第15届先天性代谢病国际大会上公布Palynziq®(Pegvaliase-Pqpz)治疗青少年苯丙酮尿症关键3期试验的积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1174292197","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174292197?lang=zh_cn&edition=full","pubTime":"2025-09-06 23:21","pubTimestamp":1757172077,"startTime":"0","endTime":"0","summary":"Biomarin在第15届先天性代谢病国际大会上宣布，其药物Palynziq®(Pegvaliase-Pqpz)用于治疗青少年苯丙酮尿症患者的关键性3期临床试验获得积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4566","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","IE00B19Z3581.USD","BK4139"],"gpt_icon":0},{"id":"1159302131","title":"拜玛林制药：Raymond James首次覆盖并给予跑赢大盘评级，目标价85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159302131","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159302131?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:56","pubTimestamp":1756900608,"startTime":"0","endTime":"0","summary":"Raymond James开始覆盖拜玛林制药，给予该股跑赢大盘评级，并设定目标价为85美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BMRN","IE0002270589.USD","IE00B19Z3B42.SGD","BK4139","IE00B7SZLL34.SGD","BK4566"],"gpt_icon":0},{"id":"2558031975","title":"拜玛林制药8月8日成交额为2.03亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558031975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558031975?lang=zh_cn&edition=full","pubTime":"2025-08-09 09:26","pubTimestamp":1754702780,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日，拜玛林制药成交额为2.03亿美元，成交额较昨日增加62.11%，当日成交量为352.34万股。拜玛林制药于2025年8月8日跌3.58%，报57.33美元，该股过去5个交易日跌1.39%，年初至今跌12.78%，过去60日跌4.1%。拜玛林专注于酶替代疗法、基因疗法和其他旨在解决复杂遗传疾病的先进疗法。拜玛林开发的疗法正在不断扩大，但仍处于相对早期的开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809092630a6dbe010&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809092630a6dbe010&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","BK4566","BK4139","IE00B19Z3581.USD","BMRN"],"gpt_icon":0},{"id":"2557151396","title":"拜玛林制药8月7日成交额为1.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557151396","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557151396?lang=zh_cn&edition=full","pubTime":"2025-08-08 09:26","pubTimestamp":1754616376,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，拜玛林制药成交额为1.25亿美元，成交额较昨日减少6.40%，当日成交量为210.43万股。拜玛林制药于2025年8月7日跌1.99%，报59.46美元，该股过去5个交易日涨2.78%，年初至今跌9.54%，过去60日跌3.11%。拜玛林专注于酶替代疗法、基因疗法和其他旨在解决复杂遗传疾病的先进疗法。拜玛林开发的疗法正在不断扩大，但仍处于相对早期的开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808092624a47c0039&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808092624a47c0039&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","BK4139","IE00B19Z3581.USD","BK4566","BMRN","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2557584135","title":"拜玛林制药8月6日成交额为1.34亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557584135","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557584135?lang=zh_cn&edition=full","pubTime":"2025-08-07 09:25","pubTimestamp":1754529942,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，拜玛林制药成交额为1.34亿美元，成交额较昨日减少69.34%，当日成交量为219.86万股。拜玛林制药于2025年8月6日跌2.03%，报60.67美元，该股过去5个交易日涨3.16%，年初至今跌7.7%，过去60日涨3.08%。拜玛林专注于酶替代疗法、基因疗法和其他旨在解决复杂遗传疾病的先进疗法。拜玛林开发的疗法正在不断扩大，但仍处于相对早期的开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807092547a479b761&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807092547a479b761&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","BK4566","IE0002270589.USD","IE00B7SZLL34.SGD","BK4139","IE00B19Z3B42.SGD","BMRN"],"gpt_icon":0},{"id":"2557349519","title":"拜玛林制药8月5日成交额为4.36亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557349519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557349519?lang=zh_cn&edition=full","pubTime":"2025-08-06 09:25","pubTimestamp":1754443508,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，拜玛林制药成交额为4.36亿美元，成交额较昨日增加7.94%，当日成交量为698.96万股。拜玛林制药于2025年8月5日涨2.69%，报61.93美元，该股过去5个交易日涨6.35%，年初至今跌5.78%，过去60日涨3.53%。拜玛林专注于酶替代疗法、基因疗法和其他旨在解决复杂遗传疾病的先进疗法。拜玛林开发的疗法正在不断扩大，但仍处于相对早期的开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806092510a4778db1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806092510a4778db1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4139","BK4566","IE00B19Z3581.USD","BMRN"],"gpt_icon":0},{"id":"1174103853","title":"异动解读 | 拜玛林制药盘前大涨6.95%，二季度业绩远超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1174103853","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174103853?lang=zh_cn&edition=full","pubTime":"2025-08-05 19:03","pubTimestamp":1754391814,"startTime":"0","endTime":"0","summary":"生物制药公司拜玛林制药今日盘前股价大涨6.95%，引发投资者广泛关注。这一显著涨幅主要源于公司发布的2025年第二季度财报远超市场预期，并上调了全年业绩指引。根据公司公布的财报，拜玛林制药第二季度调整后每股收益达1.23美元，远高于分析师平均预期的0.83美元。除了亮眼的财务业绩外，拜玛林制药管理层还上调了2025年全年收入、非GAAP运营利润率和每股收益的指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"gpt_icon":0},{"id":"2557355882","title":"拜玛林制药8月4日成交额为4.04亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557355882","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557355882?lang=zh_cn&edition=full","pubTime":"2025-08-05 09:24","pubTimestamp":1754357087,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日，拜玛林制药成交额为4.04亿美元，成交额较昨日增加83.46%，当日成交量为673.23万股。拜玛林制药于2025年8月4日涨3.73%，报60.31美元，该股过去5个交易日涨3.73%，年初至今跌8.25%，过去60日涨1.67%。拜玛林专注于酶替代疗法、基因疗法和其他旨在解决复杂遗传疾病的先进疗法。拜玛林开发的疗法正在不断扩大，但仍处于相对早期的开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805092455a6d35867&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805092455a6d35867&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","BK4566","IE0002270589.USD","IE00B7SZLL34.SGD","BK4139","IE00B19Z3B42.SGD","BMRN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":0.1024},{"period":"3month","weight":0.0762},{"period":"6month","weight":-0.0134},{"period":"1year","weight":-0.1191},{"period":"ytd","weight":-0.0094}],"compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.003},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.102},{"period":"1year","weight":0.1618},{"period":"ytd","weight":0.0085}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.于1996年10月在特拉华州注册成立，并于1997年3月21日开始运营。该公司是一家全球性生物技术公司，致力于将基因发现的前景转化为对每位患者的生活产生深远影响的药物。T. BioMarin为代表重大未满足医疗需求的疾病和病症选择候选产品，这些疾病和病症具有很好的生物学理解，并提供了率先上市或提供优于现有产品的机会。该公司的产品组合由四个已获批准的产品和多个研究候选产品组成。","yearOnYearQuotes":[{"month":1,"riseRate":0.62963,"avgChangeRate":0.047499},{"month":2,"riseRate":0.461538,"avgChangeRate":0.013226},{"month":3,"riseRate":0.461538,"avgChangeRate":0.004784},{"month":4,"riseRate":0.5,"avgChangeRate":-0.018877},{"month":5,"riseRate":0.5,"avgChangeRate":0.006184},{"month":6,"riseRate":0.615385,"avgChangeRate":0.016976},{"month":7,"riseRate":0.653846,"avgChangeRate":0.039526},{"month":8,"riseRate":0.555556,"avgChangeRate":0.001992},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.012768},{"month":10,"riseRate":0.407407,"avgChangeRate":-0.026394},{"month":11,"riseRate":0.814815,"avgChangeRate":0.061245},{"month":12,"riseRate":0.62963,"avgChangeRate":0.034544}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}